In this clinical trial, patients with stage IV melanoma received so-called Lipovaxin-MM polycomponent vaccine consisting of MM200 melanoma cell line derived plasma membrane vesicles (PMVs) containing melanoma antigens (gp100, tyrosinase and MART-1). This evidence concerns the gene PMEL and melanoma.